NCT02750059View on ClinicalTrials.gov

Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions

Acute HIV InfectionHIV CNS Involvement

Interventions

DRUG

TDF/3TC/EFV + Telmisartan

The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily

DRUG

TDF/3TC/EFV only

Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.

Trial Locations (1)

10330

SEARCH Thailand, Bangkok

All Listed Sponsors

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

SEARCH Research Foundation

OTHER

NCT02750059 - Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis | Biotech Hunter | Biotech Hunter